BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gagelmann N, Wolschke C, Klyuchnikov E, Christopeit M, Ayuk F, Kröger N. TKI Maintenance After Stem-Cell Transplantation for FLT3-ITD Positive Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis. Front Immunol 2021;12:630429. [PMID: 33790903 DOI: 10.3389/fimmu.2021.630429] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Jones RJ, Bacigalupo A. The next horizon now that everyone has a donor: Precision allogeneic transplantation. Blood Reviews 2022. [DOI: 10.1016/j.blre.2022.100990] [Reference Citation Analysis]
2 Algeri M, Merli P, Locatelli F, Pagliara D. The Role of Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Leukemia. J Clin Med 2021;10:3790. [PMID: 34501237 DOI: 10.3390/jcm10173790] [Reference Citation Analysis]
3 Serroukh Y, Hébert J, Busque L, Mercier F, Rudd CE, Assouline S, Lachance S, Delisle J. Blasts in context: the impact of the immune environment on acute myeloid leukemia prognosis and treatment. Blood Reviews 2022. [DOI: 10.1016/j.blre.2022.100991] [Reference Citation Analysis]
4 Yeoh ZH, Bajel A, Wei AH. New Drugs Bringing New Challenges to AML: A Brief Review. J Pers Med 2021;11:1003. [PMID: 34683144 DOI: 10.3390/jpm11101003] [Reference Citation Analysis]
5 Chi SG, Minami Y. Emerging Targeted Therapy for Specific Genomic Abnormalities in Acute Myeloid Leukemia. Int J Mol Sci 2022;23:2362. [PMID: 35216478 DOI: 10.3390/ijms23042362] [Reference Citation Analysis]
6 Kim T, Park S, Kwag D, Lee J, Lee J, Min G, Park S, Jeon Y, Shin S, Yahng S, Yoon J, Lee S, Cho B, Eom K, Kim Y, Lee S, Min C, Cho S, Lee J, Kim H. Depth of Response to Intensive Chemotherapy Has Significant Prognostic Value among Acute Myeloid Leukemia (AML) Patients Undergoing Allogeneic Hematopoietic Stem-Cell Transplantation with Intermediate or Adverse Risk at Diagnosis Compared to At-Risk Group According to European Leukemia Net 2017 Risk Stratification. Cancers 2022;14:3199. [DOI: 10.3390/cancers14133199] [Reference Citation Analysis]
7 Klyuchnikov E, Badbaran A, Massoud R, Fritsche-friedland U, Janson D, Ayuk F, Christopeit M, Wolschke C, Bacher U, Kröger N. Post-transplant MFC-MRD status on day +100 predicts outcomes for refractory AML patients. Transplantation and Cellular Therapy 2022. [DOI: 10.1016/j.jtct.2022.01.014] [Reference Citation Analysis]
8 Ishii H, Yano S. New Therapeutic Strategies for Adult Acute Myeloid Leukemia. Cancers 2022;14:2806. [DOI: 10.3390/cancers14112806] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]